Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Uterine Cervical Neoplasms 2Solid Tumor 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Non-squamous Non-small-cell Lung Cancer 1Non Squamous Non Small Cell Lung 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Advanced Solid Tumor 1Advanced NSCLC 1

Interventions

Imatinib Mesylate 26Sunitinib 22nilotinib 12ripretinib 11regorafenib 7avapritinib 7tanespimycin 2pexidartinib 2masitinib 2famitinib 2Midazolam 2IDRX-42 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2umbralisib 1trastuzumab deruxtecan 1trametinib 1tinostamustine 1spartalizumab 1ribociclib 1repaglinide 1ponatinib 1perifosine 1pembrolizumab 1olverembatinib 1olaratumab 1motesanib diphosphate 1dabrafenib 1cediranib 1binimetinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Stromal Tumors × famitinib × Clear all
NCT04409223 2024-02-09

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
185 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02336724 2018-04-17

A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
88 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡